Cargando…

Mitochondria-associated membranes (MAMs): a potential therapeutic target for treating Alzheimer’s disease

Alzheimer's disease (AD), a progressive neurodegenerative disorder, is a leading global health concern for individuals and society. However, the potential mechanisms underlying the pathogenesis of AD have not yet been elucidated. Currently, the most widely acknowledged hypothesis is amyloid cas...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Weiwei, Jin, Haiqiang, Huang, Yining
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796309/
https://www.ncbi.nlm.nih.gov/pubmed/33404051
http://dx.doi.org/10.1042/CS20200844
_version_ 1783634651773927424
author Yu, Weiwei
Jin, Haiqiang
Huang, Yining
author_facet Yu, Weiwei
Jin, Haiqiang
Huang, Yining
author_sort Yu, Weiwei
collection PubMed
description Alzheimer's disease (AD), a progressive neurodegenerative disorder, is a leading global health concern for individuals and society. However, the potential mechanisms underlying the pathogenesis of AD have not yet been elucidated. Currently, the most widely acknowledged hypothesis is amyloid cascade owing to the brain characteristics of AD patients, including great quantities of extracellular β-amyloid (Aβ) plaques and intracellular neurofibrillary tangles (NFTs). Nevertheless, the amyloid cascade hypothesis cannot address certain pathologies that precede Aβ deposition and NFTs formation in AD, such as aberrant calcium homeostasis, abnormal lipid metabolism, mitochondrial dysfunction and autophagy. Notably, these earlier pathologies are closely associated with mitochondria-associated membranes (MAMs), the physical structures connecting the endoplasmic reticulum (ER) and mitochondria, which mediate the communication between these two organelles. It is plausible that MAMs might be involved in a critical step in the cascade of earlier events, ultimately inducing neurodegeneration in AD. In this review, we focus on the role of MAMs in the regulation of AD pathologies and the potential molecular mechanisms related to MAM-mediated pathological changes in AD. An enhanced recognition of the preclinical pathogenesis in AD could provide new therapeutic strategies, shifting the modality from treatment to prevention.
format Online
Article
Text
id pubmed-7796309
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Portland Press Ltd.
record_format MEDLINE/PubMed
spelling pubmed-77963092021-01-21 Mitochondria-associated membranes (MAMs): a potential therapeutic target for treating Alzheimer’s disease Yu, Weiwei Jin, Haiqiang Huang, Yining Clin Sci (Lond) Aging Alzheimer's disease (AD), a progressive neurodegenerative disorder, is a leading global health concern for individuals and society. However, the potential mechanisms underlying the pathogenesis of AD have not yet been elucidated. Currently, the most widely acknowledged hypothesis is amyloid cascade owing to the brain characteristics of AD patients, including great quantities of extracellular β-amyloid (Aβ) plaques and intracellular neurofibrillary tangles (NFTs). Nevertheless, the amyloid cascade hypothesis cannot address certain pathologies that precede Aβ deposition and NFTs formation in AD, such as aberrant calcium homeostasis, abnormal lipid metabolism, mitochondrial dysfunction and autophagy. Notably, these earlier pathologies are closely associated with mitochondria-associated membranes (MAMs), the physical structures connecting the endoplasmic reticulum (ER) and mitochondria, which mediate the communication between these two organelles. It is plausible that MAMs might be involved in a critical step in the cascade of earlier events, ultimately inducing neurodegeneration in AD. In this review, we focus on the role of MAMs in the regulation of AD pathologies and the potential molecular mechanisms related to MAM-mediated pathological changes in AD. An enhanced recognition of the preclinical pathogenesis in AD could provide new therapeutic strategies, shifting the modality from treatment to prevention. Portland Press Ltd. 2021-01 2021-01-06 /pmc/articles/PMC7796309/ /pubmed/33404051 http://dx.doi.org/10.1042/CS20200844 Text en © 2021 The Author(s). https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the .
spellingShingle Aging
Yu, Weiwei
Jin, Haiqiang
Huang, Yining
Mitochondria-associated membranes (MAMs): a potential therapeutic target for treating Alzheimer’s disease
title Mitochondria-associated membranes (MAMs): a potential therapeutic target for treating Alzheimer’s disease
title_full Mitochondria-associated membranes (MAMs): a potential therapeutic target for treating Alzheimer’s disease
title_fullStr Mitochondria-associated membranes (MAMs): a potential therapeutic target for treating Alzheimer’s disease
title_full_unstemmed Mitochondria-associated membranes (MAMs): a potential therapeutic target for treating Alzheimer’s disease
title_short Mitochondria-associated membranes (MAMs): a potential therapeutic target for treating Alzheimer’s disease
title_sort mitochondria-associated membranes (mams): a potential therapeutic target for treating alzheimer’s disease
topic Aging
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796309/
https://www.ncbi.nlm.nih.gov/pubmed/33404051
http://dx.doi.org/10.1042/CS20200844
work_keys_str_mv AT yuweiwei mitochondriaassociatedmembranesmamsapotentialtherapeutictargetfortreatingalzheimersdisease
AT jinhaiqiang mitochondriaassociatedmembranesmamsapotentialtherapeutictargetfortreatingalzheimersdisease
AT huangyining mitochondriaassociatedmembranesmamsapotentialtherapeutictargetfortreatingalzheimersdisease